398 related articles for article (PubMed ID: 15853652)
1. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction.
Sillerud LO; Larson RS
Curr Protein Pept Sci; 2005 Apr; 6(2):151-69. PubMed ID: 15853652
[TBL] [Abstract][Full Text] [Related]
2. Structural analysis of protein-ligand interactions: the binding of endogenous compounds and of synthetic drugs.
Gallina AM; Bork P; Bordo D
J Mol Recognit; 2014 Feb; 27(2):65-72. PubMed ID: 24436123
[TBL] [Abstract][Full Text] [Related]
3. Development of small molecules designed to modulate protein-protein interactions.
Che Y; Brooks BR; Marshall GR
J Comput Aided Mol Des; 2006 Feb; 20(2):109-30. PubMed ID: 16622794
[TBL] [Abstract][Full Text] [Related]
4. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
5. The role of cation-pi interactions in biomolecular association. Design of peptides favoring interactions between cationic and aromatic amino acid side chains.
Pletneva EV; Laederach AT; Fulton DB; Kostic NM
J Am Chem Soc; 2001 Jul; 123(26):6232-45. PubMed ID: 11427046
[TBL] [Abstract][Full Text] [Related]
6. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.
Goodman SL; Hölzemann G; Sulyok GA; Kessler H
J Med Chem; 2002 Feb; 45(5):1045-51. PubMed ID: 11855984
[TBL] [Abstract][Full Text] [Related]
7. Heterocyclic Scaffolds in the Design of Peptidomimetic Integrin Ligands: Synthetic Strategies, Structural Aspects, and Biological Activity.
De Marco R; Mazzotti G; Greco A; Gentilucci L
Curr Top Med Chem; 2016; 16(3):343-59. PubMed ID: 26265351
[TBL] [Abstract][Full Text] [Related]
8. Arginine mimetic structures in biologically active antagonists and inhibitors.
Masic LP
Curr Med Chem; 2006; 13(30):3627-48. PubMed ID: 17168727
[TBL] [Abstract][Full Text] [Related]
9. Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.
Van der Poorten O; Knuhtsen A; Sejer Pedersen D; Ballet S; Tourwé D
J Med Chem; 2016 Dec; 59(24):10865-10890. PubMed ID: 27690430
[TBL] [Abstract][Full Text] [Related]
10. The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components.
Seebach D; Beck AK; Bierbaum DJ
Chem Biodivers; 2004 Aug; 1(8):1111-239. PubMed ID: 17191902
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy.
Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL
Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470
[TBL] [Abstract][Full Text] [Related]
12. Integrin Ligands with α/β-Hybrid Peptide Structure: Design, Bioactivity, and Conformational Aspects.
De Marco R; Tolomelli A; Juaristi E; Gentilucci L
Med Res Rev; 2016 May; 36(3):389-424. PubMed ID: 26777675
[TBL] [Abstract][Full Text] [Related]
13. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
14. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.
Groner B; Weber A; Mack L
Bioengineered; 2012; 3(6):320-5. PubMed ID: 22825353
[TBL] [Abstract][Full Text] [Related]
15. Caspase-3 binds diverse P4 residues in peptides as revealed by crystallography and structural modeling.
Fang B; Fu G; Agniswamy J; Harrison RW; Weber IT
Apoptosis; 2009 May; 14(5):741-52. PubMed ID: 19283487
[TBL] [Abstract][Full Text] [Related]
16. Peptidomimetics Targeting Protein-Protein Interactions for Therapeutic Development.
Zhang G; Andersen J; Gerona-Navarro G
Protein Pept Lett; 2018; 25(12):1076-1089. PubMed ID: 30381055
[TBL] [Abstract][Full Text] [Related]
17. Beta-amino acids: versatile peptidomimetics.
Steer DL; Lew RA; Perlmutter P; Smith AI; Aguilar MI
Curr Med Chem; 2002 Apr; 9(8):811-22. PubMed ID: 11966446
[TBL] [Abstract][Full Text] [Related]
18. SRC homology-2 inhibitors: peptidomimetic and nonpeptide.
Sawyer TK; Bohacek RS; Dalgarno DC; Eyermann CJ; Kawahata N; Metcalf CA; Shakespeare WC; Sundaramoorthi R; Wang Y; Yang MG
Mini Rev Med Chem; 2002 Oct; 2(5):475-88. PubMed ID: 12370048
[TBL] [Abstract][Full Text] [Related]
19. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
20. How different are structurally flexible and rigid binding sites? Sequence and structural features discriminating proteins that do and do not undergo conformational change upon ligand binding.
Gunasekaran K; Nussinov R
J Mol Biol; 2007 Jan; 365(1):257-73. PubMed ID: 17059826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
